Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

Study Purpose

The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies including evaluation of nutritional intervention. Further, the study will also include psychosocial and other patient-reported outcomes and medical contributors to understand their contributions to the nutritional failure in the adult advanced lung disease population. Finally, the study will evaluate both established and emerging nutritional and body composition parameters and link them to clinical outcomes in adults with CF across the spectrum of pulmonary function.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Cohort 1: Patients are eligible if their percentage of predicated forced expiratory volume in1 second (FEV1) is 60% or lower at screening.
  • - Cohort 2: Patients are eligible if their percentage of predicted forced expiratory volume in 1 second (FEV1) is 60% or greater at screening.
  • - Both cohorts match by age, gender, race and CFTR genotype severity.

Exclusion Criteria:

  • - No prior solid organ transplantation.
  • - No initiation of an investigation drug within 28 days prior to and including Visit 1.
  • - No initiation of new chronic therapy (e.g., ibuprofen, azithromycin, inhaled tobramycin, Cayston, CFTR modulator) within 28 days prior to and including Visit 1.
  • - No acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids for respiratory tract symptoms within 14 days prior to and including Visit 1.
  • - For the BIA sub-study - Individuals with an implanted pacemaker will be excluded.
  • - No initiation of a drug for weight loss (such as a GLP-1 receptor agonist) or bariatric surgery within 6-months prior to and including the Baseline visit.
  • - Patients with continued rapid change or extreme GI symptoms related to weight loss therapy should be excluded at the discretion of the study investigator.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05639556
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Jaeb Center for Health Research
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Adam SteinJessica AlvarezMelissa Putman
Principal Investigator Affiliation NorthwesternEmory UniversityMassachusetts General Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Cystic Fibrosis
Arms & Interventions

Arms

: Cohort 1

Forced expiratory volume in 1 second (FEV1) <60% predicted during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation). If no stable spirometry data are available in the 12 months prior to enrollment, from the prior 24 months will be used.

: Cohort 2

FEV1 ≥60% predicted during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation).

Interventions

Diagnostic Test: - BMI and lean mass index from DXA

Estimate and compare correlation between lean mass index from DXA and BMI

Diagnostic Test: - Anthropometric Measurements

Skinfold will be assessed with calipers. Circumference will be measured with a tape measure.

Diagnostic Test: - Hand-grip strength

A small, handheld dynamometer will be used to measure grip strength, a measure of function, on each hand.

Diagnostic Test: - Six-minute walk Test

This will be another functional assessment of fitness. Participants will be asked to walk at their normal pace for 6 minutes.The total distance walked in that time will be measured.

Diagnostic Test: - Sit-to-Stand Test

This will be used as a functional assessment of fitness and lower extremity strength. Participants will start seated on a chair and be asked to complete as many sit-to-stand repetitions without using their arms for one minute.

Diagnostic Test: - Short physical performance battery (SPPB)

This is an assessment of frailty. The test is completed in approximately 8 minutes. The test consists of 3 assessments: 1) Balance tests where the participant stands and tries to balance with their feet in various positions for 10 seconds each without assistance (side-by-side, heel-to-side, and heel-to-toe); 2) Two 4-meter gait speed tests; and 3) Chair-stand tests (single chair stand, 5 chair stands).

Diagnostic Test: - BIA Sub-study

A minimum of 50 individuals will be enrolled. Body composition will be assessed at each study visit using study bioelectrical impendence analysis (BIA).

Diagnostic Test: - Accelerometry to assess physical activity

Participants will be provided with a wrist-worn accelerometer/heart rate monitor at the baseline study visit and asked to wear it continuously for at least 3-10 days (two weekdays, one weekend day). Approximately every 3 months, the participant will be asked to again wear the accelerometer. Participants will be able to keep their accelerometers.

Other: - Gastrointestinal (GI) and nutrition questionnaires:

Subjects will complete surveys regarding gastrointestinal (GI) symptoms, including the Patient Assessment of Constipation (PAC-SYM) Score, Patient Assessment of Gastrointestinal Symptoms (PACGI-SYM) Score, the Bristol Stool Chart, and the scored Patient-Generated Subjective Global Assessment (PG-SGA).

Other: - Psychosocial questionnaire: PHQ-8

This is an 8-item scale that measures depressive symptoms over the past two weeks.

Other: - Psychosocial questionnaire: GAD-7

This is a 7-items scale that measures anxiety symptoms over the past two weeks, from not at all to nearly every day.

Other: - Psychosocial questionnaire: The Treatment Self-Regulation Questionnaire (TSRQ)

This is a 15-item scale that assesses the degree to which participants' motivation is autonomous or self-regulated.

Other: - Psychosocial questionnaire: CF Fatalism Scale

The CF Fatalism Scale measures the belief in a lack of personal power or control over one's future and has 13 items.

Other: - Psychosocial questionnaire: Body Esteem Scale for Adolescents and Adults (BESAA)

The Body Esteem Scale for Adolescents and Adults (BESAA) is 23-item measurement of self-evaluations of one's body or appearance.

Other: - 12-month Questionnaire

A short questionnaire designed to explore participants' perspectives of the acceptability and feasibility of nutritional assessments used in STRONG-CF will be given to all study participants at the end of the study.

Other: - Oral glucose tolerance testing (OGTT)

For subjects without previously diagnosed CFRD, an OGTT will be performed at baseline and 12-months with samples analyzed at the central lab.

Device: - Continuous glucose monitoring (CGM)

Subjects will wear a Dexcom G6Pro sensor in blinded mode for three 10-day periods to collect comprehensive glucose data.

Diagnostic Test: - Chest CT scans (When available within the past 6 months in medical records)

Standard of Care chest CT images will be drawn from the medical record, as available, from enrolled participants. FEV1 measurements prior to chest CT scans will be recorded to account for possible illness occurring at the time of scanning. Quantitative assessment of the pectoralis muscle area will be performed on the first single axial image above the aortic arch. Any additional standard of care chest CT's that are performed while the participant is enrolled in the study will also be collected and have a quantitative assessment of the pectoralis muscle performed.

Diagnostic Test: - Hologic Dual X-Ray Absorptiometry (DXA)

DXA measurements for whole body, total hip and lumbar spine will be acquired using the Hologic DXA and standard positioning as noted in the DXA Manual of Operations. DXA will be used to estimate total and regional body composition, which will include body fat and lean body mass. This will be used as the gold standard from which to validate BIA and MAMC.

Diagnostic Test: - Ultrasound Sub-study of assessment of appendage muscles using ultrasound

A minimum of 50 individuals will be enrolled. At each study visit, participants will undergo ultrasound muscle measurements (cross-sectional area and muscle thickness) of the biceps and quadriceps on each (left and right) side of the body (4 total areas). These measurements will be obtained in triplicate for each patient.

Diagnostic Test: - Psychosocial questionnaire: Hunger Vital Sign questionnaire

Screening tool for identifying households at risk of food insecurity and poor health outcomes linked to food insecurity with 3-items over the last 12 months.

Other: - Respiratory symptom questionnaire: CRISS

Chronic Respiratory Infection Symptom Score (CRISS) is an 8-item respiratory symptom questionnaire covering the last 24-hours.

Diagnostic Test: - Spirometry

Spirometry will be performed in accordance with the current American Thoracic Society recommendations for the performance and interpretation of tests.

Other: - Psychosocial questionnaire: Additional Health Questionnaire

Single question over the last 3 months/90 days about cannabis use for GI problems and appetite. The clinical sites will not see the responses to this question. It will be completed by the participant online either during the study visit or at home.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

University of Arizona, Tucson, Arizona

Status

Recruiting

Address

University of Arizona

Tucson, Arizona, 85724

Site Contact

Cori Daines

cdaines@arizona.edu

(813) 975-8690

Little Rock, Arkansas

Status

Recruiting

Address

University of Arkansas for Medical Sciences (UAMS)

Little Rock, Arkansas, 72205

Site Contact

Rajani Jagana

RJagana@uams.edu

501-686-5525

Yale University School of Medicine, New Haven, Connecticut

Status

Not yet recruiting

Address

Yale University School of Medicine

New Haven, Connecticut, 06520

Site Contact

Marie Egan

marie.egan@yale.edu

203-785-5852

Emory, Atlanta, Georgia

Status

Recruiting

Address

Emory

Atlanta, Georgia, 30324

Site Contact

William Hunt

randy.hunt@emory.edu

404-778-7929

Northwestern University, Chicago, Illinois

Status

Recruiting

Address

Northwestern University

Chicago, Illinois, 60611

Site Contact

Adam Stein

adam.stein@northwestern.edu

312-695-4077

University of Iowa, Iowa City, Iowa

Status

Not yet recruiting

Address

University of Iowa

Iowa City, Iowa, 52242

Site Contact

Tahuanty Pena

tahuanty-pena@uiowa.edu

319-384-7645

University of Kentucky, Lexington, Kentucky

Status

Recruiting

Address

University of Kentucky

Lexington, Kentucky, 40508

Site Contact

Mark Wurth

mark.wurth@uky.edu

859-257-5087

Tulane University, New Orleans, Louisiana

Status

Not yet recruiting

Address

Tulane University

New Orleans, Louisiana, 70112

Site Contact

Ross Klingsberg

rklingsb@tulane.edu

504-400-4316

John Hopkins University, Baltimore, Maryland

Status

Recruiting

Address

John Hopkins University

Baltimore, Maryland, 21287

Site Contact

Noah Lechtzin

nlechtz@jhmi.edu

410-955-1167

Massachusetts General Hospital (MGH), Boston, Massachusetts

Status

Recruiting

Address

Massachusetts General Hospital (MGH)

Boston, Massachusetts, 02114

Site Contact

Melissa Putman

msputman@partners.org

(813) 975-8690

Boston, Massachusetts

Status

Recruiting

Address

Boston Children's Hospital and Brigham and Women's CF Center

Boston, Massachusetts, 02120

University of Minnesota, Minneapolis, Minnesota

Status

Recruiting

Address

University of Minnesota

Minneapolis, Minnesota, 55455

Site Contact

Joanne Billings

billi001@umn.edu

612-625-7995

Saint Louis, Missouri

Status

Recruiting

Address

Washington University School of Medicine (St. Louis)

Saint Louis, Missouri, 63110

Site Contact

Jeffrey Atkinson

atkinsonj@wustl.edu

314-747-2940

New York Medical College (NYMC), Hawthorne, New York

Status

Recruiting

Address

New York Medical College (NYMC)

Hawthorne, New York, 10532

Site Contact

Allen Dozor

Allen_dozor@nymc.edu

914-404-0152

New Hyde Park, New York

Status

Not yet recruiting

Address

Northwell LIJ Adult Cystic Fibrosis Center

New Hyde Park, New York, 11040

Site Contact

Janice Wang

jwang@northwell.edu

516-465-5412

University of Cincinnati, Cincinnati, Ohio

Status

Recruiting

Address

University of Cincinnati

Cincinnati, Ohio, 45220

Site Contact

Veronica Indihar

indihama@ucmail.uc.edu

513-558-7036

University Hospitals, Cleveland, Ohio

Status

Recruiting

Address

University Hospitals

Cleveland, Ohio, 44106

Site Contact

Kimberly McBennett

kimberly.McBennett@uhhospitals.org

216-286-0709

University of Oklahoma Sciences Center, Oklahoma City, Oklahoma

Status

Recruiting

Address

University of Oklahoma Sciences Center

Oklahoma City, Oklahoma, 73104

Site Contact

Nighat F Mehdi

nighat-mehdi@ouhsc.edu

405-271-6216

Oregon Health and Science University, Portland, Oregon

Status

Recruiting

Address

Oregon Health and Science University

Portland, Oregon, 97239

Site Contact

Aaron Trimble

trimblea@ohsu.edu

503-418-8108

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Status

Recruiting

Address

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15224

Site Contact

Joseph Pilewski

pilewskijm@upmc.edu

412-692-5873

Medical University of South Carolina, Charleston, South Carolina

Status

Recruiting

Address

Medical University of South Carolina

Charleston, South Carolina, 29425

Site Contact

Christina Mingora

mingora@musc.edu

843-792-3710

Baylor University, Houston, Texas

Status

Not yet recruiting

Address

Baylor University

Houston, Texas, 77030

Site Contact

Sunjay Devarajan

sunjay.devarajan@bcm.edu

832-822-3300

Charlottesville, Virginia

Status

Recruiting

Address

University of Virginia Cystic Fibrosis Center

Charlottesville, Virginia, 22908

Site Contact

Linsay Somerville

LL7Y@hscmail.mcc.virginia.edu

434-297-7773

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.